Search

You searched for "prostatic"

494 results found
The Journal of Urology cover image with Editor's Choice stamp.

Cardiac failure and medical therapy for LUTS / BPH

11 August 2021 | | URO - Functional / Reconstructive Urology, URO - Infection
Alpha blockers (AB), 5-alpha reductase inhibitors (5-ARI) and combination therapy are widely prescribed for lower urinary tract symptoms (LUTS) considered consequent to prostatic enlargement and are the mainstay of first-line therapy. This retrospective interrogation of a large population-based dataset of...

An update on antibiotic prophylaxis in TRUS-guided prostate biopsy

1 November 2016 | | URO - Urologic Oncology, URO - Infection
Since its inception in the 1980s, transrectal ultrasound (TRUS)-guided prostate biopsy has remained the standard tool for the histological diagnosis of prostate cancer. There are several advantages to this technique which have led to the widespread use of TRUS in...

MRI screening for prostate cancer: a step towards a ‘prostagram’

7 January 2020 | | URO - Urologic Oncology, URO - Technology
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

The EP2 receptor – a novel target for prostate cancer?

1 July 2014 | | URO - Basic Science Research, URO - Urologic Oncology
This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...

Consensus statements on PSA testing in asymptomatic men in the UK

1 May 2016 | | URO - Urologic Oncology
In January 2016, the UK National Screening Committee once again recommended against a systematic population screening programme for prostate cancer due to the, as yet, insufficient evidence that the benefits of screening would outweigh the harm to the population as...

Bladder outlet obstruction

1 May 2016 | | URO - Functional / Reconstructive Urology
Case 1 Define the zonal anatomy of the prostate: A, B and C What is the significance of Zone A and Zone C? Clasify the types of lower urinary tract symptoms (LUTS) Which investigations should be routinely undertaken for a...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | URO - Urologic Oncology, URO - Technology
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

New charity launches to highlight urethral strictures – men’s silent epidemic

5 March 2025
A new charity, the Collaboration for Urological Research and Education (CURE), has today called for urgent action to address one of Britain’s biggest silent epidemics – urethral strictures. Launching Stricture Awareness Month (SAM) in March, CURE has called on healthcare...

Men with a susceptibility to prostate cancer: implications of ethnicity in PCa risk-prediction and diagnosis

5 January 2022 | | URO - Urologic Oncology
The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...

PREDICT Prostate – individualised, evidence-based estimates of survival and treatment benefit

5 November 2019 | | URO - Urologic Oncology, URO - Technology
Earlier this year ‘PREDICT Prostate’ was launched online alongside a high-profile publication in PLOS Medicine. The prognostic model and decision-aid has been designed to inform treatment decision-making among men newly diagnosed with non-metastatic prostate cancer. David Thurtle and Vincent Gnanapragasam...

Prostate cancer

1 July 2015 | | URO - Urologic Oncology
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...